Article(id=1327673608945643820, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1327673520487772831, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2022.02.016, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1632326400000, receivedDateStr=2021-09-23, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794471655354, onlineDateStr=2026-11-12, pubDate=1644422400000, pubDateStr=2022-02-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794471655354, onlineIssueDateStr=2026-11-12, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794471655354, creator=13701087609, updateTime=1794471655354, updator=13701087609, issue=Issue{id=1327673520487772831, tenantId=1146029695717560320, journalId=1319690259887390882, year='2022', volume='53', issue='2', pageStart='167', pageEnd='282', issueExtLink='null', onlineDate='null', pubDate='1644422400000', pubDateStr='2022-02-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794471634265, creator='13701087609', updateTime=1794472302153, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1327676322282844211, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1327673520487772831, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1327676322282844212, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1327673520487772831, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=277, endPage=282, ext={EN=ArticleExt(id=1327673609151164717, articleId=1327673608945643820, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=Introduction and Analysis of US FDA"Product-specific Guidances for Generic Drug Development" of Topical Drugs, columnId=1322624444787438528, journalTitle=Chinese Journal of Pharmaceuticals, columnName=Pharmaceutical Management & Information, runingTitle=null, highlight=null, articleAbstract=null, authors=Zhen CHEN, authorsList=Zhen CHEN, authorCompany=null, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1327673609700618542, articleId=1327673608945643820, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=美国FDA《仿制药开发的个药指导原则》中局部外用药的生物等效性评价方法介绍和分析, columnId=1322624444934239170, journalTitle=中国医药工业杂志, columnName=药学管理与信息, runingTitle=null, highlight=null, articleAbstract=

为了明确国外先进监管机构对皮肤局部外用仿制药生物等效性评价的要求,该文汇总了美国FDA截至2021年4月发布的《仿制药开发个药指导原则》中收录的局部外用药生物等效性评价方法,介绍和分析了美国FDA评价局部外用仿制药生物等效性的常用研究方法和相关规定,以期为我国局部外用仿制药的开发、评价,以及制定适合我国国情的局部外用药生物等效性评价个药指导原则提供借鉴与参考。

, authors=陈振, authorsList=陈振, authorCompany=null, correspAuthors=null, authorNote=

陈振(1983—),男,中级工程师,从事药物临床研究、药物立项评价工作。E-mail:

, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=GmAJDRTnRGuM6GMCRF/RjA==, magXml=+yjTfDZ9Y+5DJIqN9/1GPA==, pdfUrl=null, pdf=ir/PQbTzqCKbEbvvdpgSGA==, pdfFileSize=1470915, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=8zBupzVwgojhvHTHBRNSZA==, mapNumber=null, fund=null)}, authors=[Author(id=1327673609969054003, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=chzhcpu@163.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327673610027774261, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, authorId=1327673609969054003, language=EN, stringName=Zhen CHEN, firstName=Zhen, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Chongqing Huapont Pharm Co., Ltd., Chongqing 401121, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327673610082300214, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, authorId=1327673609969054003, language=CN, stringName=陈振, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=重庆华邦制药有限公司,重庆 401121, bio={"content":"

陈振(1983—),男,中级工程师,从事药物临床研究、药物立项评价工作。E-mail:

"}, bioImg=null, bioContent=

陈振(1983—),男,中级工程师,从事药物临床研究、药物立项评价工作。E-mail:

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327673609893556527, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, xref=null, ext=[AuthorCompanyExt(id=1327673609901945136, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, companyId=1327673609893556527, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Chongqing Huapont Pharm Co., Ltd., Chongqing 401121), AuthorCompanyExt(id=1327673609906139441, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, companyId=1327673609893556527, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=重庆华邦制药有限公司,重庆 401121)])])], keywords=[Keyword(id=1327673610166186295, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, language=CN, orderNo=1, keyword=仿制药), Keyword(id=1327673610237489464, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, language=CN, orderNo=2, keyword=局部外用药物), Keyword(id=1327673610304598329, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, language=CN, orderNo=3, keyword=生物等效), Keyword(id=1327673610401067322, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, language=CN, orderNo=4, keyword=血管收缩试验), Keyword(id=1327673610476564795, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, language=CN, orderNo=5, keyword=药代动力学)], refs=[Reference(id=1327673610573033788, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=LU M, XING H, CHEN X, et al.Advance in bioequivalence assessment of topical dermatological products [J].Asian J Pharm Sci, 2016, 11(6): 700-707., articleTitle=null, refAbstract=null), Reference(id=1327673610644336957, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=郭涤亮,王亚敏,马玉楠.皮肤局部外用仿制药研发和评价用参比制剂选择的一般考虑[J].中国新药杂志,2019,28(6):661-665., articleTitle=null, refAbstract=null), Reference(id=1327673610711445822, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=李丽,杨进波.局部皮肤用药的生物等效性研究进展[J].中国临床药理学杂志,2016,32(24):2337-2340., articleTitle=null, refAbstract=null), Reference(id=1327673610778554687, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=BRADDY A C, DAVIT B M, STIER E M, et al.Survey of international regulatory bioequivalence recommendations for approval of generic topical dermatological drug products[J].AAPS J, 2015, 17(1): 121-133., articleTitle=null, refAbstract=null), Reference(id=1327673610837274944, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理局药品审评中心.皮肤外用化学仿制药研究技术指导原则(试行)[EB/OL].(2021-03-16)[2021-07-21].https://www.cde.org.cn/main/news/viewInfoCommon/4e790f4ad1cb21091e5a8bf4a107c535., articleTitle=null, refAbstract=null), Reference(id=1327673612552745281, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on adapalene; benzoyl peroxide[EB/OL].[2021-09-21].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207917.pdf., articleTitle=null, refAbstract=null), Reference(id=1327673612645019970, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=MCKENZIE A W, STOUGHTON R B.Method for comparing percutaneous absorption of steroids [J].Arch Dermatol, 1962, 86(5): 608-610., articleTitle=null, refAbstract=null), Reference(id=1327673612699545923, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=STOUGHTON R B.Vasoconstrictor activity and percutaneous absorption of glucocorticosteroids.A direct comparison [J].Arch Dermatol, 1969, 99(6): 753-756., articleTitle=null, refAbstract=null), Reference(id=1327673612779237700, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=CHILD K J, ENGLISH A F, GILBERT H G, et al.Vasoconstrictor and systemic activities of topical steroids [J].Arch Dermatol, 1968, 97(4): 407-410., articleTitle=null, refAbstract=null), Reference(id=1327673612850540869, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=CDER.Topical dermatologic corticosteroids: in vivo bioequivalence [EB/OL].[2021-07-21].https://www.fda.gov/media/70931/download., articleTitle=null, refAbstract=null), Reference(id=1327673612909261126, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=LOCKE C S.An exact confidence interval from untransformed data for the ratio of two formulation means[J].J Pharmacokinet Biopharm, 1984, 12: 649-55., articleTitle=null, refAbstract=null), Reference(id=1327673612988952903, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on acyclovir [EB/OL].[2021-07-21].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Acyclovir_topicalcream_RLD21478_RV12-16.pdf., articleTitle=null, refAbstract=null), Reference(id=1327673613043478856, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on fluorouracil [EB/OL].[2021-07-21].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fluorouracil_sol2_16831_RC03-11.pdf., articleTitle=null, refAbstract=null), Reference(id=1327673613102199113, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on calcipotriene [EB/OL].[2021-07-21].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Calcipotriene_sol_20611_RC08-10.pdf., articleTitle=null, refAbstract=null), Reference(id=1327673613165113674, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=YU L X, LI B V.FDA bioequivalence standards [M].New York: AAPS Press/Springer, 2014: 338., articleTitle=null, refAbstract=null), Reference(id=1327673613228028235, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理局药品审评中心.地奈德乳膏初步剂量持续时间-效应研究及人体生物等效性试验(登记号CTR20201444)[EB/OL].(2020-07-29)[2021-07-21].http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml., articleTitle=null, refAbstract=null), Reference(id=1327673613295137100, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理局药品审评中心.地奈德乳膏人体生物等效性研究(登记号CTR20210811).[2021-05-21].http://www.chinadrugtrials.org.cn/clinicaltrials.searchlist.dhtml., articleTitle=null, refAbstract=null), Reference(id=1327673613366440269, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHAO L, KIM M J, ZHANG L, et al.Generating model integrated evidence for generic drug development and assessment [J].Clin Pharmacol Ther, 2019, 105(2): 338-349., articleTitle=null, refAbstract=null), Reference(id=1327673613429354830, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on ivermectin [EB/OL].[2021-07-21].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ivermectin Topical Cream 1 NDA 206255 PSG Page RV May 2019.pdf., articleTitle=null, refAbstract=null), Reference(id=1327673613488075087, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=DAVIT B M.Regulatory approaches for generic drugs: BE of topical drug products [EB/OL].(2013-03-11)[2021-07-21].https://pqri.org/wp-content/uploads/2015/08/pdf/Davit.pdf., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1327673609893556527, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, xref=null, ext=[AuthorCompanyExt(id=1327673609901945136, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, companyId=1327673609893556527, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Chongqing Huapont Pharm Co., Ltd., Chongqing 401121), AuthorCompanyExt(id=1327673609906139441, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, companyId=1327673609893556527, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=重庆华邦制药有限公司,重庆 401121)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2022.02.016, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2022.02.016, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2022.02.016, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2022.02.016, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1644422400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
美国FDA《仿制药开发的个药指导原则》中局部外用药的生物等效性评价方法介绍和分析
陈振
中国医药工业杂志 | 药学管理与信息 2022,53(2): 277-282
收起
收藏切换
中国医药工业杂志 |药学管理与信息 2022 , 53 (2) : 277 -282
美国FDA《仿制药开发的个药指导原则》中局部外用药的生物等效性评价方法介绍和分析
全屏
[Author(id=1327673609969054003, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=chzhcpu@163.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327673610027774261, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, authorId=1327673609969054003, language=EN, stringName=Zhen CHEN, firstName=Zhen, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Chongqing Huapont Pharm Co., Ltd., Chongqing 401121, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327673610082300214, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, authorId=1327673609969054003, language=CN, stringName=陈振, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=重庆华邦制药有限公司,重庆 401121, bio={"content":"

陈振(1983—),男,中级工程师,从事药物临床研究、药物立项评价工作。E-mail:

"}, bioImg=null, bioContent=

陈振(1983—),男,中级工程师,从事药物临床研究、药物立项评价工作。E-mail:

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327673609893556527, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, xref=null, ext=[AuthorCompanyExt(id=1327673609901945136, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, companyId=1327673609893556527, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Chongqing Huapont Pharm Co., Ltd., Chongqing 401121), AuthorCompanyExt(id=1327673609906139441, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673608945643820, companyId=1327673609893556527, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=重庆华邦制药有限公司,重庆 401121)])])]
陈振
作者信息
  • 重庆华邦制药有限公司,重庆 401121
作者简介:

陈振(1983—),男,中级工程师,从事药物临床研究、药物立项评价工作。E-mail:

Introduction and Analysis of US FDA"Product-specific Guidances for Generic Drug Development" of Topical Drugs
Zhen CHEN
Affiliations
  • Chongqing Huapont Pharm Co., Ltd., Chongqing 401121
出版时间: 2022-02-10 doi: 10.16522/j.cnki.cjph.2022.02.016
文章导航
收藏切换

为了明确国外先进监管机构对皮肤局部外用仿制药生物等效性评价的要求,该文汇总了美国FDA截至2021年4月发布的《仿制药开发个药指导原则》中收录的局部外用药生物等效性评价方法,介绍和分析了美国FDA评价局部外用仿制药生物等效性的常用研究方法和相关规定,以期为我国局部外用仿制药的开发、评价,以及制定适合我国国情的局部外用药生物等效性评价个药指导原则提供借鉴与参考。

仿制药  /  局部外用药物  /  生物等效  /  血管收缩试验  /  药代动力学
陈振. 美国FDA《仿制药开发的个药指导原则》中局部外用药的生物等效性评价方法介绍和分析. 中国医药工业杂志, 2022 , 53 (2) : 277 -282 . DOI: 10.16522/j.cnki.cjph.2022.02.016
Zhen CHEN. Introduction and Analysis of US FDA"Product-specific Guidances for Generic Drug Development" of Topical Drugs[J]. Chinese Journal of Pharmaceuticals, 2022 , 53 (2) : 277 -282 . DOI: 10.16522/j.cnki.cjph.2022.02.016

参考文献 引证文献
排序方式:
[1]
LU M, XING H, CHEN X, et al.Advance in bioequivalence assessment of topical dermatological products [J].Asian J Pharm Sci, 2016, 11(6): 700-707.
[2]
郭涤亮,王亚敏,马玉楠.皮肤局部外用仿制药研发和评价用参比制剂选择的一般考虑[J].中国新药杂志,2019,28(6):661-665.
[3]
李丽,杨进波.局部皮肤用药的生物等效性研究进展[J].中国临床药理学杂志,2016,32(24):2337-2340.
[4]
BRADDY A C, DAVIT B M, STIER E M, et al.Survey of international regulatory bioequivalence recommendations for approval of generic topical dermatological drug products[J].AAPS J, 2015, 17(1): 121-133.
[5]
国家药品监督管理局药品审评中心.皮肤外用化学仿制药研究技术指导原则(试行)[EB/OL].(2021-03-16)[2021-07-21].https://www.cde.org.cn/main/news/viewInfoCommon/4e790f4ad1cb21091e5a8bf4a107c535.
[6]
FDA.Draft guidance on adapalene; benzoyl peroxide[EB/OL].[2021-09-21].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207917.pdf.
[7]
MCKENZIE A W, STOUGHTON R B.Method for comparing percutaneous absorption of steroids [J].Arch Dermatol, 1962, 86(5): 608-610.
[8]
STOUGHTON R B.Vasoconstrictor activity and percutaneous absorption of glucocorticosteroids.A direct comparison [J].Arch Dermatol, 1969, 99(6): 753-756.
[9]
CHILD K J, ENGLISH A F, GILBERT H G, et al.Vasoconstrictor and systemic activities of topical steroids [J].Arch Dermatol, 1968, 97(4): 407-410.
[10]
CDER.Topical dermatologic corticosteroids: in vivo bioequivalence [EB/OL].[2021-07-21].https://www.fda.gov/media/70931/download.
[11]
LOCKE C S.An exact confidence interval from untransformed data for the ratio of two formulation means[J].J Pharmacokinet Biopharm, 1984, 12: 649-55.
[12]
[13]
FDA.Draft guidance on fluorouracil [EB/OL].[2021-07-21].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fluorouracil_sol2_16831_RC03-11.pdf.
[14]
FDA.Draft guidance on calcipotriene [EB/OL].[2021-07-21].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Calcipotriene_sol_20611_RC08-10.pdf.
[15]
YU L X, LI B V.FDA bioequivalence standards [M].New York: AAPS Press/Springer, 2014: 338.
[16]
国家药品监督管理局药品审评中心.地奈德乳膏初步剂量持续时间-效应研究及人体生物等效性试验(登记号CTR20201444)[EB/OL].(2020-07-29)[2021-07-21].http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml.
[17]
国家药品监督管理局药品审评中心.地奈德乳膏人体生物等效性研究(登记号CTR20210811).[2021-05-21].http://www.chinadrugtrials.org.cn/clinicaltrials.searchlist.dhtml.
[18]
ZHAO L, KIM M J, ZHANG L, et al.Generating model integrated evidence for generic drug development and assessment [J].Clin Pharmacol Ther, 2019, 105(2): 338-349.
[20]
DAVIT B M.Regulatory approaches for generic drugs: BE of topical drug products [EB/OL].(2013-03-11)[2021-07-21].https://pqri.org/wp-content/uploads/2015/08/pdf/Davit.pdf.
2022年第53卷第2期
85
15
0
引用本文
BibTeX
文章信息
doi: 10.16522/j.cnki.cjph.2022.02.016
  • 接收时间:2021-09-23
  • 首发时间:2026-11-12
  • 出版时间:2022-02-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2021-09-23
基金
作者信息
    重庆华邦制药有限公司,重庆 401121
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2022.02.016
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏